{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-024952","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.589776+00:00","generated_at":"2026-05-15T18:09:46.443728+00:00","sec_items":["8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Allarity closes $20M non-convertible debt with Streeterville; extends cash runway to mid-2028","bullets":["Closed $20M non-convertible debt financing with Streeterville Capital via two promissory notes: $10.93M and $10M.","Net proceeds extend cash runway into summer 2028; funds Phase 2 ovarian cancer trial and FDA preparation.","Proceeds also support pivotal trial prep, companion diagnostic strategy, and potential expansion into other WNT-driven tumors.","Stenoparib has shown durable clinical benefit; some patients on therapy >30 months in Phase 2."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-024952","json":"https://secwatch.observer/filing/0001213900-26-024952.json","markdown":"https://secwatch.observer/filing/0001213900-26-024952.md","text":"https://secwatch.observer/filing/0001213900-26-024952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026024952/0001213900-26-024952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026024952/ea0280539-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:09:46.443728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}